Development of innovative high-throughput in vivo screening technology for validation of oncology drug candidates using a novel cellular double barcoding technology

UAB Cureline Baltic is implementing project "Development of innovative high-throughput in vivo screening technology for validation of oncology drug candidates using a novel cellular double barcoding technology" project, co-financed by the European Regional Development Fund, provided in 2014–2020 year of the European Union Funds Investment Operational Program Priority 1 "Promotion of Research, Experimental Development and Innovation" Measure No. 01.2.1-LVPA-K-823 "SmartInvest LT+".

The aim of the project is to increase the company's innovation potential and competitiveness.

During the implementation of the project, it is planned to carry out research related to the development of an innovative high-throughput in vivo research technology for the evaluation of oncology drug candidates using a new cell double barcoding technology.

Project implementation period from November 2021 until August 2023.

The total value of the project is EUR 3587481,85. The amount of support allocated from the European Regional Development Fund to the project is EUR 2329370,69.